Author

M. Philpott

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Immunology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 7 Approach:experimental assay· 5 Assay:bulk RNA-seq· 4 Research Focus:cancer & tumor microenvironment· 3 Approach:statistical model· 3 Research Focus:drug response / drug discovery· 2 Research Focus:gene regulatory network inference· 2 Approach:genetic perturbation / CRISPR· 2

Frequent Co-Authors

A. P. Cribbs· 5 shared U. Oppermann· 4 shared A. C. Aksu· 2 shared A. Cingoz· 2 shared H. Syed· 2 shared J. Dunford· 2 shared T. Bagci-Onder· 2 shared T. T. Onder· 2 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

A. P. Cribbs

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Chromatin-focused genetic and chemical screens identify BRPF1 as a targetable vulnerability in Taxol-resistant triple-negative breast cancer

O. Yedier-Bayram, A. Cingoz, E. Yilmaz, A. C. Aksu, B. Esin, N. Pinarbasi Degirmenci, A. D. Cavga, B. Dedeoglu, B. Cevatemre, H. Syed, M. Philpott, A. P. Cribbs, U. Oppermann, N. Lack, C. ACILAN AYHAN, , T. Bagci-Onder

The paper identifies BRPF1 as a key regulator of Taxol resistance in TNBC through genetic and chemical screens, showing its inhibition sensitizes resistant cells to chemotherapy.

bioRxiv · Apr 16, 2024Cancer Biology

BRD9-SMAD2/3 orchestrates stemness and tumorigenesis in pancreatic ductal adenocarcinoma

Y. Feng, L. Cai, M. Pook, F. Liu, C.-H. Chang, M. A. Mouti, R. Nibhani, S. Wu, S. Deng, S. Militi, J. Dunford, M. Philpott, Y. Fan, G.-C. Fan, Q. Liu, , S. Pauklin

This study identifies BRD9 as a key regulator of pancreatic cancer stem cell stemness and tumorigenesis, showing that its inhibition reduces CSC self-renewal and enhances chemotherapy response.

bioRxiv · Mar 2, 2023Cancer Biology

Epigenetic-focused CRISPR/Cas9 screen identifies ASH2L as a regulator of glioblastoma cell survival

E. Ozyerli-Goknar, E. Y. Kala, A. C. Aksu, I. Bulut, A. Cingoz, S. Nizamuddin, M. Biniossek, F. Seker-Polat, T. Morova, C. Aztekin, S. H. A. Kung, H. Syed, N. Tuncbag, M. Gonen, M. Philpott, , T. Bagci-Onder

This study uses CRISPR/Cas9 screens to identify ASH2L as a key regulator of glioblastoma cell survival, with downstream effects on cell cycle and apoptosis.

bioRxiv · Aug 17, 2022 · PreprintCancer Biology

The Prolyl-tRNA Synthetase Inhibitor Halofuginone Inhibits SARS-CoV-2 Infection

D. R. Sandoval, T. Mandel Clausen, C. Nora, J. A. Magida, A. P. Cribbs, A. Denardo, A. E. Clark, A. F. Garretson, J. K. C. Coker, A. Narayanan, S. A. Majowicz, M. Philpott, C. Johansson, J. E. Dunford, C. B. Spliid, , Mazitsch

This study identifies halofuginone as a potent inhibitor of SARS-CoV-2 infection and replication by reducing heparan sulfate biosynthesis and suppressing viral replication.

bioRxiv · Mar 22, 2021 · PreprintMicrobiology

Interleukin-17A causes osteoarthritis-like transcriptional changes in human osteoarthritis-derived chondrocytes and synovial fibroblasts in vitro

J. Y. Mimpen, M. J. Baldwin, A. P. Cribbs, M. Philpott, A. J. Carr, S. G. Dakin, S. J. B. Snelling

This study shows IL-17A induces OA-like gene expression in OA-derived chondrocytes and synovial fibroblasts, with secukinumab inhibiting these effects.

bioRxiv · Mar 5, 2021Immunology

KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas

J. A. Heward, L. Koniali, A. D'Avola, K. Close, A. Yeomans, M. Philpott, J. Dunford, T. Rahim, A. F. Al Seraihi, J. Wang, K. Korfi, S. Araf, S. Iqbal, F. Bewicke-Copley, E. Kumar, , J. Fitzgibbon

This study shows that inhibiting KDM5 demethylases restores H3K4 methylation and reactivates genes in KMT2D mutant lymphomas, offering a potential therapeutic strategy.

bioRxiv · Jun 30, 2020Cancer Biology

Histone H3K27me3 demethylases regulate human Th17 cell development and effector functions by impacting on metabolism

A. P. Cribbs, S. Terlecki-Zaniewicz, M. Philpott, J. Baardman, D. Ahern, M. Lindow, S. Obad, H. Oerum, B. Sampey, P. Mander, H. Penn, P. Wordsworth, P. Bowness, R. K. Prinjha, M. de Winther, , U. Oppermann

This study identifies KDM6A and KDM6B as regulators of human Th17 cell development and effector functions by affecting metabolism and cytokine production.

bioRxiv · Oct 30, 2019Immunology